Thorsten Schlomm

List of Publications by Year in Descending Order

221 papers	10,140 citations	48 h-index	95 g-index
242 ext. papers	11,920 ext. citations	6.3 avg, IF	5.32 L-index

#	Paper	IF	Citations
221	Evolution of Targeted Prostate Biopsy by Adding Micro-Ultrasound to the Magnetic Resonance Imaging Pathway. *European Urology Focus*, **2021**, 7, 1292-1299	5.1	15
220	Chromosome 5 harbors two independent deletion hotspots at 5q13 and 5q21 that characterize biologically different subsets of aggressive prostate cancer. *International Journal of Cancer*, **2021**, 148, 748-758	7.5	2
219	Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer. *Cancer Biology and Medicine*, **2021**, 18, 245-255	5.2	1
218	Overexpression of the TRIM24 E3 Ubiquitin Ligase is Linked to Genetic Instability and Predicts Unfavorable Prognosis in Prostate Cancer. *Applied Immunohistochemistry and Molecular Morphology* , **2021**, 29, e29-e38	1.9	0
217	Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy. *Clinical Genitourinary Cancer*, **2021**, 19, 296-304.e3	3.3	3
216	Upregulation of Phosphatase 1 Nuclear-Targeting Subunit (PNUTS) Is an Independent Predictor of Poor Prognosis in Prostate Cancer. *Disease Markers*, **2020**, 2020, 7050146	3.2	2
215	Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2020**, 477, 625-636	5.1	1
214	A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy. *British Journal of Cancer*, **2020**, 123, 604-609	8.7	3
213	Robot-Assisted versus Laparoscopic Donor Nephrectomy: A Comparison of 250 Cases. *Journal of Clinical Medicine*, **2020**, 9,	5.1	2
212	Up regulation of the Hippo signalling effector YAP1 is linked to early biochemical recurrence in prostate cancers. *Scientific Reports*, **2020**, 10, 8916	4.9	5
211	The impact of long-term androgen deprivation therapy on cognitive function and socioeconomic decision making in prostate cancer patients. *Psycho-Oncology*, **2020**, 29, 1338-1346	3.9	7
210	Should We Perform Old-for-Old Kidney Transplantation during the COVID-19 Pandemic? The Risk for Post-Operative Intensive Stay. *Journal of Clinical Medicine*, **2020**, 9,	5.1	1
209	Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion. *Molecular Medicine*, **2020**, 26, 24	6.2	2
208	Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion-positive prostate cancers. *International Journal of Cancer*, **2020**, 147, 575-583	7.5	2
207	Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERG-negative prostate cancer. *Prostate*, **2020**, 80, 1097-1107	4.2	5
206	Subcellular Compartmentalization of Survivin is Associated with Biological Aggressiveness and Prognosis in Prostate Cancer. *Scientific Reports*, **2020**, 10, 3250	4.9	3
205	High CHK2 protein expression is a strong and independent prognostic feature in ERG negative prostate cancer. *Pathology*, **2020**, 52, 421-430	1.6	2

204	Prostatakarzinom: Onkologische Kennzeichen. *Springer Reference Medizin*, **2020**, 1-18	0	
203	Repeat Radiation for Local Recurrence of Head and Neck Tumors and in Prostate Cancer. *Deutsches Ärzteblatt International*, **2020**, 117, 167-174	2.5	2
202	Therapie bei isoliertem PSA-Anstieg. *Springer Reference Medizin*, **2020**, 1-12	0	
201	Loss of cytoplasmic survivin expression is an independent predictor of poor prognosis in radically operated prostate cancer patients. *Cancer Medicine*, **2020**, 9, 1409-1418	4.8	4
200	High RSF1 protein expression is an independent prognostic feature in prostate cancer. *Acta Oncologica*, **2020**, 59, 268-273	3.2	4
199	Expression of CCCTC-binding factor (CTCF) is linked to poor prognosis in prostate cancer. *Molecular Oncology*, **2020**, 14, 129-138	7.9	8
198	Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer. *World Journal of Urology*, **2020**, 38, 2185-2196	4	6
197	Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions. *Pathology and Oncology Research*, **2020**, 26, 2709-2722	2.6	4
196	Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence. *BioMed Research International*, **2020**, 2020, 5845374	3	3
195	High B7-H3 expression is linked to increased risk of prostate cancer progression. *Pathology International*, **2020**, 70, 733-742	1.8	8
194	Xenograft-derived mRNA/miR and protein interaction networks of systemic dissemination in human prostate cancer. *European Journal of Cancer*, **2020**, 137, 93-107	7.5	4
193	EGFR as a stable marker of prostate cancer dissemination to bones. *British Journal of Cancer*, **2020**, 123, 1767-1774	8.7	4
192	Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer. *BMC Cancer*, **2020**, 20, 1220	4.8	3
191	Tumor-Associated Release of Prostatic Cells into the Blood after Transrectal Ultrasound-Guided Biopsy in Patients with Histologically Confirmed Prostate Cancer. *Clinical Chemistry*, **2020**, 66, 161-168	5.5	13
190	The gordian knots. *World Journal of Urology*, **2020**, 38, 1815-1817	4	
189	Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy. *Prostate Cancer and Prostatic Diseases*, **2020**, 23, 102-107	6.2	16
188	Solid organ transplantation programs facing lack of empiric evidence in the COVID-19 pandemic: A By-proxy Society Recommendation Consensus approach. *American Journal of Transplantation*, **2020**, 20, 1826-1836	8.7	62
187	Upregulation of PTTG1 is associated with poor prognosis in prostate cancer. *Pathology International* , **2020**, 70, 441-451	1.8	4

186	Random forest-based modelling to detect biomarkers for prostate cancer progression. *Clinical Epigenetics*, **2019**, 11, 148	7.7	32
185	Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of deleted prostate cancers. *Cancer Biology and Medicine*, **2019**, 16, 319-330	5.2	1
184	SNW1 is a prognostic biomarker in prostate cancer. *Diagnostic Pathology*, **2019**, 14, 33	3	2
183	Prostate cancer prognosis in men with other malignancies prior to radical prostatectomy. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 575.e1-575.e7	2.8	2
182	Response to olaparib in a germline mutated prostate cancer and genetic events associated with resistance. *Journal of Physical Education and Sports Management*, **2019**, 5,	2.8	21
181	Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer. *BMC Cancer*, **2019**, 19, 193	4.8	13
180	Active Surveillance und die moderne Diagnostik des Prostatatkarzinoms. *Onkologe*, **2019**, 25, 304-314	0.1	
179	Radikale Prostatektomie beim lokal fortgeschrittenen und metastasierten Prostatakarzinom. *Onkologe*, **2019**, 25, 315-321	0.1	
178	Aktive Überwachung des Prostatakarzinoms. *Uro-News*, **2019**, 23, 46-50	0	
177	Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy. *Neoplasia*, **2019**, 21, 872-881	6.4	2
176	Analysis of the Effects of Day-Time vs. Night-Time Surgery on Renal Transplant Patient Outcomes. *Journal of Clinical Medicine*, **2019**, 8,	5.1	7
175	Native Nephrectomy before and after Renal Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). *Journal of Clinical Medicine*, **2019**, 8,	5.1	4
174	High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer. *BMC Cancer*, **2019**, 19, 944	4.8	0
173	Up regulation of Rho-associated coiled-coil containing kinase1 (ROCK1) is associated with genetic instability and poor prognosis in prostate cancer. *Aging*, **2019**, 11, 7859-7879	5.6	7
172	A nuclear shift of GSK3β protein is an independent prognostic factor in prostate cancer. *Oncotarget*, **2019**, 10, 1729-1744	3.3	2
171	Nuclear ELAC2 overexpression is associated with increased hazard for relapse after radical prostatectomy. *Oncotarget*, **2019**, 10, 4973-4986	3.3	3
170	Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues. *Oncotarget*, **2019**, 10, 5439-5453	3.3	12
169	Nuclear up regulation of the BRCA1-associated ubiquitinase BAP1 is associated with tumor aggressiveness in prostate cancers lacking the TMPRSS2:ERG fusion. *Oncotarget*, **2019**, 10, 7096-7111	3.3	3

168	Upregulation of SPDEF is associated with poor prognosis in prostate cancer. *Oncology Letters*, **2019**, 18, 5107-5118	2.6	3
167	A Novel Gene Signature-Based Model Predicts Biochemical Recurrence-Free Survival in Prostate Cancer Patients after Radical Prostatectomy. *Cancers*, **2019**, 12,	6.6	30
166	Aktive Überwachung des Prostatakarzinoms. *Im Focus Onkologie*, **2019**, 22, 54-58	0	
165	Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers. *Prostate*, **2019**, 79, 302-311	4.2	2
164	A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer. *International Journal of Cancer*, **2019**, 144, 1685-1696	7.5	11
163	5q21 deletion is often heterogeneous in prostate cancer. *Genes Chromosomes and Cancer*, **2019**, 58, 509-515	3	3
162	Contemporary approach to predict early biochemical recurrence after radical prostatectomy: update of the Walz nomogram. *Prostate Cancer and Prostatic Diseases*, **2018**, 21, 386-393	6.2	8
161	Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence. *Prostate*, **2018**, 78, 676-681	4.2	13
160	High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer. *BMC Cancer*, **2018**, 18, 37	4.8	14
159	Immunohistochemically detected IDH1 mutation is rare and mostly heterogeneous in prostate cancer. *World Journal of Urology*, **2018**, 36, 877-882	4	20
158	Integrating Tertiary Gleason 5 Patterns into Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. *European Urology*, **2018**, 73, 674-683	10.2	32
157	Incidence, Risk Factors, Management, and Complications of Rectal Injuries During Radical Prostatectomy. *European Urology Focus*, **2018**, 4, 554-557	5.1	22
156	Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes. *European Urology Focus*, **2018**, 4, 376-384	5.1	5
155	13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer. *Genes Chromosomes and Cancer*, **2018**, 57, 504-512	5	22
154	The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes. *Prostate Cancer*, **2018**, 2018, 5821616	1.9	5
153	PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer. *BMC Cancer*, **2018**, 18, 612	4.8	12
152	Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer. *European Urology*, **2018**, 74, 376-386	10.2	40
151	Upregulation of centromere protein F is linked to aggressive prostate cancers. *Cancer Management and Research*, **2018**, 10, 5491-5504	3.6	11

150	Development and Characterization of a Spontaneously Metastatic Patient-Derived Xenograft Model of Human Prostate Cancer. *Scientific Reports*, **2018**, 8, 17535	4.9	14
149	Deletion of 3p13 is a late event linked to progression of : fusion prostate cancer. *Cancer Management and Research*, **2018**, 10, 5909-5917	3.6	2
148	Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories. *Cancer Cell*, **2018**, 34, 996-1011.e8	24.3	89
147	High concordance of TMPRSS-ERG fusion between primary prostate cancer and its lymph node metastases. *Oncology Letters*, **2018**, 16, 6238-6244	2.6	3
146	Up regulation of the steroid hormone synthesis regulator HSD3B2 is linked to early PSA recurrence in prostate cancer. *Experimental and Molecular Pathology*, **2018**, 105, 50-56	4.4	5
145	Oncologic and Functional Outcomes after Radical Prostatectomy for High or Very High Risk Prostate Cancer: European Validation of the Current NCCN Guideline. *Journal of Urology*, **2017**, 198, 354-361	2.5	27
144	Apurinic/apyrimidinic endonuclease 1 (APE1/Ref-1) overexpression is an independent prognostic marker in prostate cancer without TMPRSS2:ERG fusion. *Molecular Carcinogenesis*, **2017**, 56, 2135-2145	5	12
143	Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance. *BJU International*, **2017**, 120, 808-814	5.6	37
142	Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. *Cell Reports*, **2017**, 19, 2045-2059	10.6	72
141	Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers. *Neoplasia*, **2017**, 19, 279-287	6.4	11
140	High concordance of findings obtained from transgluteal magnetic resonance imaging - and transrectal ultrasonography-guided biopsy as compared with prostatectomy specimens. *BJU International*, **2017**, 120, 365-376	5.6	2
139	High-Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer. *Prostate*, **2017**, 77, 1528-1538	4.2	6
138	FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy. *Carcinogenesis*, **2017**, 38, 1180-1187	4.6	10
137	Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer. *BMC Cancer*, **2017**, 17, 504	4.8	5
136	Comparison of 11 Active Surveillance Protocols in Contemporary European Men Treated With Radical Prostatectomy. *Clinical Genitourinary Cancer*, **2017**,	3.3	9
135	Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer. *Neoplasia*, **2017**, 19, 707-715	6.4	43
134	Mitochondrial mutations drive prostate cancer aggression. *Nature Communications*, **2017**, 8, 656	17.4	66
133	Does Cytoreductive Prostatectomy Really Have an Impact on Prognosis in Prostate Cancer Patients with Low-volume Bone Metastasis? Results from a Prospective Case-Control Study. *European Urology Focus*, **2017**, 3, 646-649	5.1	42

132	Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancer. *Scientific Reports*, **2017**, 7, 2056	4.9	23
131	Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer. *Carcinogenesis*, **2017**, 38, 19-27	4.6	29
130	Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy. *BJU International*, **2017**, 119, 717-723	5.6	25
129	Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy. *European Urology*, **2017**, 71, 330-336	10.2	42
128	High-Level Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	15
127	Deletion of 8p is an independent prognostic parameter in prostate cancer. *Oncotarget*, **2017**, 8, 379-392	3.3	30
126	Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer. *Oncotarget*, **2017**, 8, 31494-31508	3.3	3
125	PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort. *Oncotarget*, **2017**, 8, 65566-65576	3.3	35
124	Deletion lengthening at chromosomes 6q and 16q targets multiple tumor suppressor genes and is associated with an increasingly poor prognosis in prostate cancer. *Oncotarget*, **2017**, 8, 108923-108935	3.3	21
123	Nerve-sparing Surgery Technique, Not the Preservation of the Neurovascular Bundles, Leads to Improved Long-term Continence Rates After Radical Prostatectomy. *European Urology*, **2016**, 69, 584-589	10.2	86
122	Salvage radical prostatectomy for recurrent prostate cancer: verification of European Association of Urology guideline criteria. *BJU International*, **2016**, 117, 55-61	5.6	32
121	p16 upregulation is linked to poor prognosis in ERG negative prostate cancer. *Tumor Biology*, **2016**, 37, 12655-12663	2.9	16
120	Heterogeneity of ERG expression in prostate cancer: a large section mapping study of entire prostatectomy specimens from 125 patients. *BMC Cancer*, **2016**, 16, 641	4.8	19
119	Quantitative comparison of DNA methylation assays for biomarker development and clinical applications. *Nature Biotechnology*, **2016**, 34, 726-37	44.5	204
118	Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers. *International Journal of Cancer*, **2016**, 138, 1199-206	7.5	21
117	Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2016**, 34, 235.e11-6	2.8	48
116	Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment. *European Urology*, **2016**, 70, 824-828	10.2	14
115	Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. *European Urology*, **2016**, 69, 592-598	10.2	167

114	Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence. *Human Pathology*, **2016**, 48, 102-10	3.7	13
113	Deletion of 18q is a strong and independent prognostic feature in prostate cancer. *Oncotarget*, **2016**, 7, 86339-86349	3.3	23
112	Heterogeneity and chronology of 6q15 deletion and ERG-fusion in prostate cancer. *Oncotarget*, **2016**, 7, 3897-904	3.3	6
111	Toxicity in a multimodality approach of radical prostatectomy with radiation and hormonal therapy.. *Journal of Clinical Oncology*, **2016**, 34, 107-107	2.2	
110	Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer. *Prostate*, **2016**, 76, 259-72	4.2	18
109	Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients. *Scientific Reports*, **2016**, 6, 39736	4.9	73
108	A Clinician Guide to Avoiding and Managing Common Complications During and After Robot-assisted Laparoscopic Radical Prostatectomy. *European Urology Focus*, **2016**, 2, 30-48	5.1	8
107	The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer. *Clinical Cancer Research*, **2016**, 22, 2802-11	12.9	13
106	Re: The Molecular Taxonomy of Primary Prostate Cancer. *European Urology*, **2016**, 69, 1157	10.2	4
105	II-tubulin overexpression is linked to aggressive tumor features and shortened survival in clear cell renal cell carcinoma. *World Journal of Urology*, **2015**, 33, 1561-9	4	10
104	Prostate cancer-associated autoantibodies in serum against tumor-associated antigens as potential new biomarkers. *Journal of Proteomics*, **2015**, 119, 218-29	3.9	24
103	VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy. *International Journal of Molecular Sciences*, **2015**, 16, 8591-606	6.3	3
102	Genomic Predictors of Outcome in Prostate Cancer. *European Urology*, **2015**, 68, 1033-44	10.2	136
101	HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer. *Experimental and Molecular Pathology*, **2015**, 98, 419-26	4.4	20
100	Tumor volume in insignificant prostate cancer: increasing threshold gains increasing risk. *Prostate*, **2015**, 75, 45-9	4.2	17
99	Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancers. *Human Pathology*, **2015**, 46, 514-23	3.7	7
98	Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters. *Carcinogenesis*, **2015**, 36, 1333-40	4.6	37
97	The Molecular Taxonomy of Primary Prostate Cancer. *Cell*, **2015**, 163, 1011-25	56.2	1713

96	The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion. *BMC Cancer*, **2015**, 15, 538	4.8	27
95	Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer. *Clinical Cancer Research*, **2015**, 21, 3471-9	12.9	36
94	BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence. *Nature Genetics*, **2015**, 47, 22-30	36.3	99
93	Safe-R: a novel score, accounting for oncological safe nerve-sparing at radical prostatectomy for localized prostate cancer. *World Journal of Urology*, **2015**, 33, 77-83	4	2
92	Oncological outcome after radical prostatectomy: Marital status does not make a difference. *International Journal of Urology*, **2015**, 22, 484-9	2.3	4
91	PSMA expression is highly homogenous in primary prostate cancer. *Applied Immunohistochemistry and Molecular Morphology*, **2015**, 23, 449-55	1.9	19
90	Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer. *International Journal of Cancer*, **2015**, 137, 2354-63	7.5	33
89	Identification of pathologically favorable disease in intermediate-risk prostate cancer patients: Implications for active surveillance candidates selection. *Prostate*, **2015**, 75, 1484-91	4.2	19
88	Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers. *PLoS ONE*, **2015**, 10, e0128525	3.7	24
87	High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate Cancer. *PLoS ONE*, **2015**, 10, e0134614	3.7	8
86	HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy. *Oncotarget*, **2015**, 6, 12822-34	3.3	26
85	Heterogeneity in D'Amico classification-based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibility. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 329.e13-9	2.8	29
84	A visual-interactive system for prostate cancer cohort analysis. *IEEE Computer Graphics and Applications*, **2015**, 35, 44-55	1.7	21
83	Prevalence of chromosomal rearrangements involving non-ETS genes in prostate cancer. *International Journal of Oncology*, **2015**, 46, 1637-42	4.4	9
82	Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion. *Oncology Reports*, **2015**, 34, 1211-20	3.5	6
81	Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy. *Journal of Urology*, **2015**, 193, 479-83	2.5	32
80	External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort. *Journal of Urology*, **2015**, 193, 1970-5	2.5	43
79	Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer. *Oncotarget*, **2015**, 6, 8377-87	3.3	33

78	Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer. *Oncotarget*, **2015**, 6, 27966-79	3.3	28
77	II-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion. *American Journal of Pathology*, **2014**, 184, 609-17	5.8	44
76	NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer. *Prostate*, **2014**, 74, 1012-22	4.2	9
75	High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions. *European Journal of Cancer*, **2014**, 50, 852-61	7.5	33
74	TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer. *European Urology*, **2014**, 66, 978-81	10.2	48
73	Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. *Cell Reports*, **2014**, 8, 798-806	10.6	177
72	Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. *Journal of Urology*, **2014**, 192, 409-14	2.5	153
71	A feasible and time-efficient adaptation of NeuroSAFE for da Vinci robot-assisted radical prostatectomy. *European Urology*, **2014**, 66, 138-44	10.2	71
70	Patterns of TPD52 overexpression in multiple human solid tumor types analyzed by quantitative PCR. *International Journal of Oncology*, **2014**, 44, 609-15	4.4	22
69	Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapse. *PLoS ONE*, **2014**, 9, e100469	3.7	15
68	CD57 expression in incidental, clinically manifest, and metastatic carcinoma of the prostate. *BioMed Research International*, **2014**, 2014, 356427	3	10
67	Comparison between complication rates of laser prostatectomy electrocautery transurethral resection of the prostate: A population-based study. *Canadian Urological Association Journal*, **2014**, 8, E419-24	1.2	4
66	High nuclear karyopherin 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy. *Modern Pathology*, **2014**, 27, 96-106	9.8	24
65	The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression. *International Journal of Cancer*, **2014**, 135, 1399-407	7.5	29
64	Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer. *Modern Pathology*, **2014**, 27, 1612-20	9.8	59
63	Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer. *International Journal of Cancer*, **2014**, 135, 1369-80	7.5	85
62	Aberrant presentation of HPA-reactive carbohydrates implies Selectin-independent metastasis formation in human prostate cancer. *Clinical Cancer Research*, **2014**, 20, 1791-802	12.9	23
61	Qualitative and Quantitative Requirements for Assessing Prognostic Markers in Prostate Cancer. *Microarrays (Basel, Switzerland)*, **2014**, 3, 137-58		2

60	Predicting radical prostatectomy outcome: Cell cycle progression (CCP) score compared with primary Gleason grade among men with clinical Gleason less than 7 who are upgraded to Gleason 7.. *Journal of Clinical Oncology*, **2014**, 32, 13-13	2.2	2
59	Prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with prostatectomy.. *Journal of Clinical Oncology*, **2014**, 32, 17-17	2.2	
58	MALDI imaging on tissue microarrays identifies molecular features associated with renal cell cancer phenotype. *Anticancer Research*, **2014**, 34, 2255-61	2.3	27
57	Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers. *Journal of Pathology*, **2013**, 231, 130-41	9.4	112
56	SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence. *Prostate*, **2013**, 73, 1690-8	4.2	34
55	Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence. *Human Pathology*, **2013**, 44, 1789-96	3.7	17
54	High mitochondria content is associated with prostate cancer disease progression. *Molecular Cancer*, **2013**, 12, 145	42.1	39
53	High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers. *Molecular Oncology*, **2013**, 7, 1001-11	7.9	40
52	High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. *European Journal of Cancer*, **2013**, 49, 1273-9	7.5	83
51	Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy. *Experimental and Molecular Pathology*, **2013**, 95, 227-34	4.4	13
50	Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. *Cancer Cell*, **2013**, 23, 159-70	24.3	259
49	Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancers. *International Journal of Cancer*, **2013**, 132, 1333-40	7.5	32
48	Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence. *Modern Pathology*, **2013**, 26, 733-42	9.8	32
47	Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. *Modern Pathology*, **2013**, 26, 975-83	9.8	121
46	Marked heterogeneity of ERG expression in large primary prostate cancers. *Modern Pathology*, **2013**, 26, 106-16	9.8	56
45	Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis. *Oncology Letters*, **2013**, 6, 1245-1252	2.6	18
44	CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. *Cancer Research*, **2013**, 73, 2795-805	10.1	169
43	Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers. *Journal of Clinical Pathology*, **2013**, 66, 563-8	3.9	25

42	High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer. *Experimental and Therapeutic Medicine*, **2013**, 5, 102-106	2.1	12
41	Value of cell cycle progression (CCP) score to predict biochemical recurrence and definitive post-surgical pathology.. *Journal of Clinical Oncology*, **2013**, 31, 5043-5043	2.2	2
40	Neurovascular structure-adjacent frozen-section examination (NeuroSAFE) increases nerve-sparing frequency and reduces positive surgical margins in open and robot-assisted laparoscopic radical prostatectomy: experience after 11,069 consecutive patients. *European Urology*, **2012**, 62, 333-40	10.2	162
39	Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patients. *BJU International*, **2012**, 110, 1714-20	5.6	11
38	Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro. *Journal of Proteome Research*, **2012**, 11, 2452-66	5.6	38
37	Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. *Cancer Discovery*, **2012**, 2, 1024-35	24.4	107
36	Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. *American Journal of Pathology*, **2012**, 181, 401-12	5.8	256
35	The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkers. *International Journal of Oncology*, **2012**, 40, 261-8	4.4	21
34	Human prostate cancer in a clinically relevant xenograft mouse model: identification of (1,6)-branched oligosaccharides as a marker of tumor progression. *Clinical Cancer Research*, **2012**, 18, 1364-73	12.9	64
33	Association of nuclear accumulation of p53 with ERG fusion and poor prognosis in prostate cancer.. *Journal of Clinical Oncology*, **2012**, 30, 124-124	2.2	
32	Inverse stage migration in patients undergoing radical prostatectomy: results of 8916 European patients treated within the last decade. *BJU International*, **2011**, 108, 1256-61	5.6	92
31	MicroRNA in prostate, bladder, and kidney cancer: a systematic review. *European Urology*, **2011**, 59, 671-81	10.2	355
30	Full functional-length urethral sphincter preservation during radical prostatectomy. *European Urology*, **2011**, 60, 320-9	10.2	138
29	TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling. *BMC Cancer*, **2011**, 11, 507	4.8	117
28	High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. *Prostate*, **2011**, 71, 281-8	4.2	179
27	Circulating miRNAs are correlated with tumor progression in prostate cancer. *International Journal of Cancer*, **2011**, 128, 608-16	7.5	448
26	ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. *Clinical Cancer Research*, **2011**, 17, 5878-88	12.9	225
25	Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platform. *PLoS ONE*, **2011**, 6, e16833	3.7	55

24	The presence of prostate cancer on saturation biopsy can be accurately predicted. *BJU International*, **2010**, 105, 636-41	5.6	16
23	Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer. *Clinical Cancer Research*, **2010**, 16, 56-64	12.9	98
22	Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. *Clinical Cancer Research*, **2010**, 16, 1553-60	12.9	113
21	Biochemical recurrence after radical prostatectomy: multiplicative interaction between surgical margin status and pathological stage. *Journal of Urology*, **2010**, 184, 1341-6	2.5	68
20	Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era. *BJU International*, **2010**, 106, 37-43	5.6	60
19	Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy. *European Urology*, **2010**, 57, 562-8	10.2	58
18	From gene to clinic: TMA-based clinical validation of molecular markers in prostate cancer. *Methods in Molecular Biology*, **2010**, 664, 177-89	1.4	8
17	Molecular cancer phenotype in normal prostate tissue. *European Urology*, **2009**, 55, 885-90	10.2	21
16	Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series. *European Urology*, **2009**, 55, 394-401	10.2	31
15	Current technique of open intrafascial nerve-sparing retropubic prostatectomy. *European Urology*, **2009**, 56, 317-24	10.2	102
14	Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis. *Prostate*, **2009**, 69, 976-81	4.2	100
13	TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. *Apmis*, **2009**, 117, 575-82	3.4	59
12	Predictive value of prostate-specific antigen expression in prostate cancer: a tissue microarray study. *Urology*, **2009**, 74, 1169-73	1.6	17
11	Clinical significance of p53 alterations in surgically treated prostate cancers. *Modern Pathology*, **2008**, 21, 1371-8	9.8	165
10	Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level European Urology, **2008**, 53, 750-7	10.2	19
9	Assessment of biochemical recurrence rate in patients with pathologically confirmed insignificant prostate cancer. *Urology*, **2008**, 72, 1208-11; discussion 1212-3	1.6	10
8	Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients. *Clinical Cancer Research*, **2008**, 14, 7838-42	12.9	55
7	Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features. *Cancer*, **2008**, 113, 2068-72	6.4	88

6	Development and external validation of an extended repeat biopsy nomogram. *Journal of Urology*, **2007**, 177, 510-5	2.5	72
5	Molecular staging of prostate cancer in the year 2007. *World Journal of Urology*, **2007**, 25, 19-30	4	35
4	Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. *Clinical Cancer Research*, **2007**, 13, 6579-84	12.9	128
3	The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomy. *European Urology*, **2006**, 49, 273-8; discussion 278-9	10.2	41
2	Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. *BJU International*, **2006**, 98, 329-34	5.6	110
1	Random forest-based modelling to detect biomarkers for prostate cancer progression		1